Aziz Nazha Discusses the Future of Treating Patients With MDS

The stem cell thrapy, Orca-T led to promising relapse-free and overall survival rates in patients with intermediate- to high-risk myelodysplastic syndrome.

The FDA recently approved Tibsovo for relapsed/refractory MDS with an IDH1 mutation, a treatment option for a disease subset with no options before this approval.

My visits to the local cancer center were very impactful as a cancer survivor, and I consider that staff a part of my family.

From actor Patrick Dempsey saying that his late mother would be proud of his work at The Dempsey Center to a “General Hospital” actor discussing his cancer treatments, here’s what’s happening in the oncology space this week.

The Food and Drug Administration approved Tibsovo for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation.

COVID is unpredictable and scary, much like cancer.